Navigation Links
Drug for erectile disorder show promise in the treatment of obesity
Date:4/1/2013

Although sildenafil is best known for promoting erections, it may also serve as a weight loss aid by coaxing our bodies to store more healthy "brown fat" relative to unhealthy "white fat" than it would otherwise do on its own. According to new research published online in The FASEB Journal, this is because sildenafil inhibits the breakdown of cyclic GMP, which has been well known as a messenger molecule used by the body to control blood pressure and flow, and has now been shown to play an important role determining which type of fatwhite or brownthe body stores.

"There is a growing need for novel treatments against obesity," said Alexander Pfeifer, M.D., Ph.D., a researcher involved in the work from the Institute of Pharmacology and Toxicology at the University of Bonn, Biomedical Center in Bonn, Germany. "Finding new positive effects of existing drugs, such as sildenafil, in adipose tissue might help to bridge the period until novel drugs against obesity have been developed."

To make this discovery, Pfeifer and colleagues used mice to show that cyclic GMP reduced the secretion of pro-inflammatory hormones, which, in turn, shifted the "color code" of fat from white to brown. Mice treated with sildenafil showed browning of the white fat after just a few days of treatment, which is believed to be the result of high cyclic GMP levels. Then the researchers used isolated fat cells and treated the cells directly with cyclic GMP and identified a "browning" effect as well.

"Clearly, size matters when it comes to our weight," said Gerald Weissmann, M.D., Editor-in-Chief of The FASEB Journal. "Numerous studies show that obesity is a risk factor for virtually every human disease, and that obesity is epidemic. The finding that Viagra and similar drugs can change our body fat composition has major implications. These drugs have well defined risk/benefit profiles and are approved for the treatment of erectile disorders. Further research will determine whether they are useful in the treatment of human girth disorders."


'/>"/>

Contact: Cody Mooneyhan
cmooneyhan@faseb.org
301-634-7104
Federation of American Societies for Experimental Biology
Source:Eurekalert

Related biology news :

1. Dysfunction in cerebellar Calcium channel causes motor disorders and epilepsy
2. Researchers spot molecular control switch for preterm lung disorders
3. New gene variant may explain psychotic features in bipolar disorder
4. Adding to the list of disease-causing proteins in brain disorders
5. 2 new genes linked to amyotrophic lateral sclerosis and related disorders
6. Genetic risk factors for common eye disorder come into focus
7. MBL scientists find genes linked to human neurological disorders in sea lamprey genome
8. Unique peptide could treat cancers, neurological disorders, and infectious diseases
9. Grant to fund development of drug candidates for rheumatoid arthritis, neurodegenerative disorders
10. Circadian rhythms can be modified for potential treatment of disorders
11. Borderline personality disorder: The "perfect storm" of emotion dysregulation
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/3/2016)... LONDON , June 3, 2016 /PRNewswire/ ... Transport Management) von Nepal ... ,Angebot und Lieferung hochsicherer geprägter Kennzeichen, einschließlich ... weltweit führend in der Produktion und Implementierung ... an der Ausschreibung im Januar teilgenommen, aber ...
(Date:6/2/2016)... 2, 2016 Perimeter Surveillance & ... Systems, Physical Infrastructure, Support & Other Service  ... offers comprehensive analysis of the global Border ... generate revenues of $17.98 billion in 2016. ... a leader in software and hardware technologies for advanced ...
(Date:5/20/2016)... May 20, 2016  VoiceIt is excited to ... VoicePass. By working together, VoiceIt and ... VoiceIt and VoicePass take slightly different approaches to ... both security and usability. ... this new partnership. "This marketing and ...
Breaking Biology News(10 mins):
(Date:6/27/2016)... 2016  Liquid Biotech USA ... a Sponsored Research Agreement with The University of ... from cancer patients.  The funding will be used ... with clinical outcomes in cancer patients undergoing a ... be employed to support the design of a ...
(Date:6/24/2016)... , June 24, 2016 Epic ... sensitively detects cancers susceptible to PARP inhibitors by ... tumor cells (CTCs). The new test has already ... therapeutics in multiple cancer types. Over ... DNA damage response pathways, including PARP, ATM, ATR, ...
(Date:6/23/2016)... ... June 23, 2016 , ... ... its second eBook, “Clinical Trials Patient Recruitment and Retention Tips.” Partnering with experienced ... this eBook by providing practical tips, tools, and strategies for clinical researchers. , ...
(Date:6/23/2016)... 23, 2016 /PRNewswire/ - FACIT has announced the ... biotechnology company, Propellon Therapeutics Inc. ("Propellon" or ... of a portfolio of first-in-class WDR5 inhibitors for ... as WDR5 represent an exciting class of therapies, ... medicine for cancer patients. Substantial advances have been ...
Breaking Biology Technology: